摘要
目的：评价唑来膦酸与阿仑膦酸钠治疗绝经后骨质疏松的疗效和安全性。方法：将初诊为绝经后骨质疏松的患者90例随机分为A、B组各45例，治疗时间均为20个月；A组静脉滴注唑来膦酸注射液5mg，每年1次，共2次；B组口服阿仑膦酸钠70mg，每周1次。两组均补充碳酸钙D3600mg／d，分别以视觉模拟疼痛评分（VAS）方法对患者治疗前和治疗后2、4个月疼痛疗效进行评估，并在治疗前和治疗后10、20个月测量腰椎L1～IJ4及髋部骨密度（BMD）。结果：两组治疗后2月VAS评分较治疗前明显下降（P〈0．05），治疗后4月较治疗前下降更明显，差异有统计学意义（P〈0．01）；两组患者治疗20个月后腰椎、髋部BMD值都有明显上升，与治疗前比较差异有统计学意义（P〈0．05）。结论：唑来膦酸与阿仑膦酸钠均能显著改善绝经后骨质疏松疼痛，增加腰椎、髋部BMD值，从药物的依从性看唑来膦酸比阿仑膦酸钠为更理想的选择。
Objective： To evaluate efficacy and safety of zoledronic acid and alendronate sodium in treatment of postmenopausal os- teoporosis. Methods： A total of 90 cases of hospital patients with newly diagnosed postmenopausal osteoporosis were randomly assigned to group A （45 cases）, B （45 cases）, treatment time was 20 months. Group A of intravenous zoledronic acid injection 5 mg, 1 time a year, a total of 2 times ; group B of oral alendronate sodium 70 mg, 1 time a week. 2 groups were supplemented calcium D3 600 mg/d, visual ana- log pain score （ Vasual analogy scale, VAS） method was used to assess the therapeutic efficacy of pain in patients before and after treatment for 2 months and 4 months , respectively, bone mineral density （BMD） of lumbar （L1 -IA） and hip were measured before and after treat- ment for 10 and 20 months Results： VAS scores decreased significantly in group A and B after treatment for 2 months compared with before treatment （ P 〈 0. 05 ）, declined more significantly after treatment for 4 months, the difference was statistically significant （P 〈 0. O1 ） ; BMD values of lumbar spine and hip increased significantly after treatment for 20 months compared with before treatment, the difference was statis- tically significant （ P 〈 0. 05 ） . Conclusion ： Zoledronic acid and alendronate sodium can significantly improve postmenopausal osteoporosis pain, increase BMD values of lumbar spine and hip, zoledronic acid is better than alendronate sodium in drug compliance
出处
《中国妇幼保健》
CAS
北大核心
2014年第8期1283-1285,共3页
Maternal and Child Health Care of China
关键词
唑来膦酸
阿仑膦酸钠绝
经后骨质疏松
Zoledronic acid
Alendronate sodium
Postmenopausal osteoporosis
